Germany· DE-A57-56633f9532085a5d
Bleo-Cell
A bleomycin product containing bleomycin, registered in Germany by Stadapharm Gmbh. The same ATC class is registered in 15 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Bleomycin is registered in 15 of 19 countries.
Countries holding a registration under ATC L01DC01 (bleomycin), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 9 of them publish a price we can compare per daily dose
Bleomycin · ATC L01DC01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Bleomycin
- Manufacturer
- Stadapharm Gmbh
- Country
- Germany (DE)
- ATC code
- L01DC01
- ATC class
- Bleomycin
- Defined daily dose
- 3 mg, P
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- August 5, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
212 interactions on record for bleomycin.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bleomycin · interactions on record
212 records
- 33 severe
- 105 moderate
- 15 minor
- 59 info
Most severe, free to view
- CladribineL01BB04severe
- Brentuximab vedotinL01FX05severe
- Brentuximab vedotinL01XC12severe
- Talimogene laherparepvecL01XL02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Bleomycin in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomBleo-Kyowa 15,000unit powder for solution for injection vialsKyowa Kirin Ltd
- NetherlandsBleomedac, poeder voor oplossing voor injectie 15000 IU (Ph. Eur.)Medac Gesellschaft für klinische Spezialpräparate mbH
- FranceBLEOMYCINE ACCORD 15000 UI, poudre pour solution injectable / pour perfusionACCORD HEALTHCARE FRANCE
- SwedenBleomycin Accord 15000 IE Pulver till injektions-/infusionsvätska, lösningAccord Healthcare B.V.
- SwitzerlandBleomycin Baxter
- SpainBLEOMICINA ACCORD 15.000 UI POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFGAccord Healthcare S.L.U.
- CanadaBLEOMYCIN FOR INJECTIONFRESENIUS KABI CANADA LTD
- NorwayBleomycin BaxterBaxter Medical AB
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Bleomycin Accord, Bleomycin Baxter
- Belgium · Bleomycine Accord
- Czechia · Bleomycin Accord
- Denmark · Bleomycin Accord, Bleomycin Baxter
- Spain · Bleomicina Accord, Bleomicina Viatris
- Finland · Bleomycin Accord
- France · Bleomycine Accord
- United Kingdom (Northern Ireland) · Bleomycin, Bleomycin Accord Healthcare
- Iceland · Bleomycin Baxter
- Netherlands · Bleomycine Accord
- Norway · Bleomycin Accord, Bleomycin Baxter
- Poland · Bleomedac, Bleomycyna
- Portugal · Bleomicina Accord
- Romania · Bleomicină Accord
- Sweden · Bleomycin Accord, Bleomycin Baxter
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3b9963ef-6fab-49a2-8828-f6fee9526192 GET /v1/drugs/3b9963ef-6fab-49a2-8828-f6fee9526192?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intramuscular Use, Intrapleural Use, Intravenous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Bleomycin",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about bleomycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.